Clinical Development Program
Parkinson’s Phase 3 Pivotal Trial Underway
The Light for PD trial was a randomized, double-blind, sham-controlled clinical study evaluating Celeste® in individuals living with Parkinson’s disease.
Key characteristics included:
- 351 participants enrolled across the United States
- Fully remote trial design
- Daily home-based device use
- Six-month treatment period
- Evaluation of motor and non-motor outcome measures
The trial has been completed and data analysis is underway.
Participant Engagement
The Parkinson’s disease community played a critical role in enabling the Light for PD trial through participation, advocacy, and awareness efforts.
Read more about the trial here. Additional details are available at www.clinicaltrials.gov (#NCT04453033).
Phase 2 Clinical Study
A randomized, double-blind, controlled Phase 2 study evaluated Celeste® in 92 individuals living with Parkinson’s disease.
The study contributed important scientific insights regarding photo-neuromodulation and informed the design of the subsequent Light for PD trial.
Published findings are available in Neurotherapeutics (read here).
Supporting Scientific Literature
A growing body of scientific literature has explored the relationship between light exposure, circadian regulation, retinal signaling pathways, and neurological function.
Pipeline
future research areas
PhotoPharmics continues to evaluate scientific opportunities related to photo-neuromodulation and neurodegenerative disease. Any future development programs would require additional research and clinical evaluation.
